WAILEA, Hawaii — In this Healio Video Perspective from Retina 2024, Jordan M. Graff, MD, FACS, describes a post hoc analysis of the YOSEMITE and RHINE clinical trials evaluating biomarkers for vascular stability.
The trials evaluated faricimab vs. aflibercept in patients with diabetic macular edema.
“In summary, we follow these markers for vascular stability and found in this subset analysis of YOSEMITE and RHINE a greater reduction in hyperreflective foci as well as greater reduction in the vascular leakage [with faricimab],” Graff said.